Skip to main content
Clinical Trials/JPRN-UMIN000038467
JPRN-UMIN000038467
Completed
未知

Proteomic analysis for establishing a biomarker panel for the onset of Adult T-cell Leukemia (ATL) - Proteomic analysis for establishing a biomarker panel for AT

niversity of the Ryukyus0 sites85 target enrollmentMarch 30, 2020

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
niversity of the Ryukyus
Enrollment
85
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 30, 2020
End Date
October 9, 2019
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
niversity of the Ryukyus

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Participants withdrawing consent through opt\-out forms available online at the homepage of the Laboratory of Hematoimmunology are excluded

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
Application of proteomics to aid biomarker discovery in smear positive patients of P.vivax and P.falciparum malaria
CTRI/2010/091/000451Department of Biosciences and Bioengineering, Indian Institute of Technology (IIT), Powai, Mumbai- 400 076100
Active, not recruiting
Not Applicable
Evaluación mediante proteómica de biomarcadores proteicos asociados con el tratamiento con Eplerenona versus espironolactona en pacientes post-infarto agudo de miocardio, diabéticos con hipertensión arterial no controlada y disfunción ventricular sistólica leve”Identification of proteomic biomarkers associated with eplerenone treatment versus spironolactone in post-acute coronary syndrome patients, with non-controlled arterial hypertension and ventricular dysfunction - PROMETEODisfunción ventricular leve-moderada post-infarto agudo de miocardio en pacientes diabéticos con hipertensión arterial no controlada.Low-moderate ventricular dysfunction in post-acute coronary syndrome patients with diabetes and non-controlled arterial hypertension.
EUCTR2008-001192-29-ESFundación Investigación y Desarrollo en el Area Cardiovascular
Active, not recruiting
Not Applicable
Identificación de biomarcadores proteicos asociados a resistencia a la aspirina y a tienopiridinas en pacientes con cardiopatía isquémica establecida. (ESTUDIO BIRAT).Identification of new protein biomarkers associated with aspirin and thienopyridine resistance in stable coronary ischaemic patients: a proteomic study. (BIRAT Study). - BIRAT
EUCTR2007-006686-32-ESFUNDACIÓN INVESTIGACIÓN BIOMEDICA DEL HOSPITAL CLINICO SAN CARLOS
Recruiting
Not Applicable
Candidate biomarker analysis in proteomics of vessel & fat tissue from patients with coronary artery bypass graft (Proteomics research center for metabolic disease)Diseases of the circulatory system
KCT0000465Seoul National University Bundang Hospital25
Active, not recruiting
Not Applicable
Proteomic profile analysis to classify advanced pancreatic adenocarcinoma patients for clinical outcome after treatment with PDXG (cisplatin, docetaxel, capecitabine, gemcitabine) or PEXG (cisplatin, epirubicin, capecitabine, gemcitabine) regimen. - NDpatients affected by adenocarcinoma at stage III or IV who are candidate to receive upfront chemotherapy according to PDXG or PEXG regimen.MedDRA version: 9.1Level: LLTClassification code 10052747Term: Adenocarcinoma pancreas
EUCTR2009-013029-41-ITFONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR